GLP-1 Drugs and Anesthesia Safety

On September 9, 2026, a team of plastic surgeons led by Roberta Albanese published a retrospective study in Aesthetic Plastic Surgery asking a specific question: does taking a GLP-1 receptor agonist change the anesthesia risk profile for a common cosmetic procedure^[1]? The procedure in question is high-definition lipoabdominoplasty, which combines liposuction with an abdominoplasty, commonly called a tummy tuck, into a single operation under general anesthesia. The study tracked 196 patients split evenly into two groups: 98 who were taking semaglutide or tirzepatide before their operation, and 98 who were not^[1].

What the study looked at

Every patient underwent the same standardized preoperative assessment and the same general anesthesia protocol, which lets the comparison isolate the GLP-1 variable instead of differences in surgical technique^[1]. The surgeons measured two kinds of outcomes. The primary outcomes were intraoperative adverse events: whether a patient's breathing became compromised during surgery, whether blood pressure or heart rate turned unstable, or whether an arrhythmia showed up on the monitor.

Secondary outcomes covered timing and comfort: how long anesthesia and surgery lasted, how oxygen and carbon dioxide levels behaved during the case, and how much pain patients reported afterward. The published abstract does not say how many surgical centers contributed patients, which matters for how broadly the result should be read.

What the study found

The result was, in the authors' own words, a lack of statistically significant differences between the two groups across intraoperative stability, recovery, and early postoperative outcomes^[1]. Blood oxygen and carbon dioxide levels stayed within normal ranges in both groups. No clinically relevant breathing problems turned up in either arm.

Time to waking after anesthesia came out similar in both groups. So did the time to first getting up and moving, and the time to hospital discharge^[1]. Complication rates matched too: seroma and infection occurred at comparable frequencies in both arms, and so did delayed wound healing and hyperpigmentation. Nausea, vomiting, and pain scores after surgery did not differ meaningfully by group^[1].

Sample size is worth sitting with here. With 98 patients per arm, the study had enough numbers to compare common outcomes but not enough to rule out rare events, aspiration among them, which occur too infrequently in either group to show up reliably in a cohort this size.

Why anesthesiologists are watching this drug class

The concern behind this kind of study is not hypothetical. GLP-1 receptor agonists slow gastric emptying as part of how they work, and food or liquid that lingers in the stomach longer than expected raises the risk of regurgitation and aspiration once a patient is sedated for surgery^[2]. In June 2023, the American Society of Anesthesiologists issued consensus-based guidance addressing exactly this concern, after reviewing case reports of patients on GLP-1 drugs who aspirated stomach contents during procedures despite following standard fasting instructions^[2].

That guidance acknowledged the evidence base was thin, limited mostly to isolated case reports rather than large trials^[2]. It still recommended caution: adjusting medication timing and dietary intake around surgery in consultation with the prescribing clinician and the surgical team, instead of applying the standard fasting window to every patient regardless of what they take^[2]. A separate 2023 JAMA analysis found that GLP-1 use for weight loss carried a higher risk of gastroparesis and bowel obstruction than another weight-loss drug, evidence that the delayed-emptying effect has real downstream consequences outside the operating room as well^[3].

What this study does not establish

A single retrospective study of 196 patients from one research group is not the end of this conversation, and the authors say so themselves^[1]. The design compares two groups after the fact instead of testing a hypothesis under controlled conditions, and the authors were explicit that the result should not be read as evidence of equivalence, because the study was never designed as a formal non-inferiority or equivalence trial^[1].

The authors called for larger, prospective studies that separate results by which specific GLP-1 drug a patient was taking, since semaglutide and tirzepatide are not identical molecules and may not carry identical risk^[1]. Complications serious enough to matter are rare enough that detecting a real difference, if one exists, needs a trial with thousands of patients rather than hundreds.

What this means for readers

For someone on semaglutide or tirzepatide facing an elective procedure, this study is a reason for cautious reassurance rather than an all-clear. It adds one data point suggesting that, with standard precautions in place, surgery under general anesthesia has not produced a measurable safety gap for patients on these drugs in this setting^[1]. It does not settle the aspiration question the ASA guidance was written to address, and it says nothing about emergency surgery, where fasting time cannot be controlled at all.

The decision about whether, and how, to adjust a GLP-1 prescription before an operation belongs to the patient's surgical and anesthesia team, not to a single retrospective study. Anyone with a procedure scheduled while taking a GLP-1 drug should raise it directly with both the prescriber and the surgical team well before the operation date, so the fasting and medication plan gets set for that individual case instead of being assumed by default.